Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and ...
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3Kα …